2015 Conquer Cancer Foundation of ASCO Young Investigator Award Funded by Kidney Cancer Association
Matthew Campbell, MD
Chief Fellow, Hematology/Oncology Fellowship, UT MD Anderson Cancer Center
New agents called immune check point inhibitors have been FDA approved in the treatment of metastatic melanoma and metastatic squamous cell lung cancer. These agents have shown exciting activity in bladder, kidney, and a variety of other cancers in early clinical studies and are being explored in larger studies. The first of these agents, ipilimumab, is an antibody that binds to CTLA-4, a molecule that is increased by T cells responding to a stimulus, to help shut off the immune response. When the ...
Source: Kidney Cancer Association - May 11, 2015 Category: Cancer & Oncology Source Type: news
2015 Conquer Cancer Foundation of ASCO Young Investigator Award Funded by Kidney Cancer Association
Matthew Campbell, MD
Chief Fellow, Hematology/Oncology Fellowship, UT MD Anderson Cancer CenterNew agents called immune check point inhibitors have been FDA approved in the treatment of metastatic melanoma and metastatic squamous cell lung cancer. These agents have shown exciting activity in bladder, kidney, and a variety of other cancers in early clinical studies and are being explored in larger studies. The first of these agents, ipilimumab, is an antibody that binds to CTLA-4, a molecule that is increased by T cells responding to a stimulus, to help shut off the immune response. When the an...
Source: Kidney Cancer Association - May 11, 2015 Category: Urology & Nephrology Source Type: news
Analysis of Gene Expression of RCC by DNA Microaray in Patients treated with Sunitinib
Gene Evaluation of DNA expression from snap-frozen renal cell cancer tissue from 5 patients with locally advanced non-metastatic tumors, submitted to nephrectomy after being treated with 2 cycles of neoadjuvant Sunitinib...05/11/2015 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - May 11, 2015 Category: Cancer & Oncology Source Type: news
2015 Conquer Cancer Foundation of ASCO Young Investigator Award
Layperson Summary
New agents called immune check point inhibitors have been FDA approved in the treatment of metastatic melanoma and metastatic squamous cell lung cancer. These agents have shown exciting activity in bladder, kidney, and a variety of other cancers in early clinical studies and are being explored in larger studies. The first of these agents, ipilimumab, is an antibody that binds to CTLA-4, a molecule that is increased by T cells responding to a stimulus, to help shut off the immune response. When the anti-body binds to CTLA-4, the immune system is able to stay activated an...
Source: Kidney Cancer Association - May 10, 2015 Category: Cancer & Oncology Source Type: news
New Study Finds That Robotically Assisted Surgery For Kidney Cancer Increases Access To Partial Versus Radical Nephrectomy, Reducing Mortality, Renal Failure And Long-Term Costs
A new study, published in the February issue of Health Affairs, found that in terms of quality-adjusted life-years gained, the benefits of robotic-assisted partial nephrectomy surgery for kidney cancer patients outweighed the health care and surgical costs to patients and payers by a ratio of five to one. (Source: Medical Design Online News)
Source: Medical Design Online News - February 6, 2015 Category: Medical Equipment Source Type: news
Patients with operable kidney cancers more likely to have partial nephrectom
Patients with operable kidney cancers were more likely to have a partial nephrectomy -- the recommended treatment for localized tumors -- when treated in hospitals that were early adopters of robotic surgery, according to a new study.12/15/2014 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - December 15, 2014 Category: Cancer & Oncology Source Type: news
Early adoption of robotic surgery leads to organ preservation for kidney cancer patients
Researchers found that partial nephrectomy -- the recommended treatment for localized kidney tumors -- was performed more frequently at hospitals that were early adopters of robotic surgery. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - December 11, 2014 Category: Science Source Type: news
Early adoption of robotic surgery leads to organ preservation for kidney cancer patients
(NYU Langone Medical Center / New York University School of Medicine) Researchers at NYU Langone Medical Center conclude that patients with operable kidney tumors were more likely to undergo a partial nephrectomy -- the recommended course of treatment -- at hospitals that were early adopters of robotic surgery. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 11, 2014 Category: Cancer & Oncology Source Type: news
Surgical robot adopters use more of recommended procedure for kidney cancer, reports Medical Care
(Wolters Kluwer Health) Hospitals with robotic surgical systems are more likely to perform 'nephron-sparing' partial nephrectomy -- a recommended alternative to removal of the entire kidney -- in patients with kidney cancer, reports a study in the December issue of Medical Care. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 11, 2014 Category: Global & Universal Source Type: news
Robotic Radical Nephrectomy for Renal Cell CarcinomaRobotic Radical Nephrectomy for Renal Cell Carcinoma
Robotic radical nephrectomy for the treatment of RCC, while effective, does not offer any advantages over the laparoscopic technique, according to a new study. BMC Urology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 4, 2014 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
Adjuvant Therapy for RCC
At the present time, the standard of care for patients who have received nephrectomy for localized renal cell carcinoma (RCC) is radiographic surveillance.09/05/2014 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - September 5, 2014 Category: Cancer & Oncology Source Type: news
Extremely delayed brain metastasis from renal cell carcinoma
Brain metastasis occurs in 3.9-24% of patients with renal cell carcinoma (RCC), with an average interval from nephrectomy to brain metastasis of 1 to 3 years.08/15/2014 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - August 15, 2014 Category: Cancer & Oncology Source Type: news
